Hyperfine (HYPR) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $3.6 million, up 56% year-over-year, with strong U.S. and international sales of the Swoop portable imaging system and a total installed base of over 160 systems globally.

• Gross margin expanded to a record 52% in Q3 2024, maintaining above 50% for the second consecutive quarter.

• Placed 13 systems in Q3 2024, with a balanced mix between U.S. and international placements and a slight improvement in average selling price.

• Advanced AI-powered software with FDA clearance of ninth-generation and CE approval, and plans for a tenth-generation launch in H1 2025.

• Clinical studies in Alzheimer's and stroke show promising results, supporting broader adoption and new care settings.

Financial highlights

• Q3 2024 revenue: $3.6 million, up 56% year-over-year; year-to-date revenue: $10.6 million, up 27%.

• Q3 gross profit: $1.9 million (52% margin); year-to-date gross profit: $5.1 million (48% margin, up 330 bps year-over-year).

• R&D expenses: $5.98 million; SG&A expenses: $6.89 million in Q3 2024.

• Net loss: $10.3 million ($0.14/share) in Q3, improved from $10.8 million ($0.15/share) year-over-year.

• Cash and equivalents at September 30, 2024: $45.8 million; cash runway expected into early 2026.

Outlook and guidance

• 2024 revenue guidance narrowed to $14–$14.5 million, representing up to 31% year-over-year growth.

• Gross margin guidance for 2024 updated to 47–50%, at the high end of previous range.

• Anticipated 2024 cash burn: $37–$40 million; cash runway expected into early 2026.

• Growth acceleration expected in the second half of 2025, driven by new care settings and international expansion.

• Recurring revenue and margin expansion anticipated as installed base grows.